NCT04670666 - Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus | Biotech Hunter

Enrollment

270

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

June 30, 2025

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

MADALENA ASSOCIATION

Madalena association coated tablet.

DRUG

METFORMIN

Metformin 1000 mg extended-release tablet.

DRUG

EMPAGLIFLOZIN + LINAGLIPTIN

Empagliflozin 10 mg + linagliptin 5 mg coated tablet.

OTHER

MADALENA ASSOCIATION PLACEBO

Madalena association placebo tablet.

OTHER

METFORMIN PLACEBO

Metformin placebo tablet.

OTHER

EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO

Empagliflozin + linagliptin placebo tablet.